Blocking IL-1 to prevent respiratory failure in COVID-19
Abstract COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the...
Main Authors: | Frank L. van de Veerdonk, Mihai G. Netea |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Critical Care |
Online Access: | http://link.springer.com/article/10.1186/s13054-020-03166-0 |
Similar Items
-
Rare variants increase the risk of severe COVID-19
by: Frank L van de Veerdonk, et al.
Published: (2021-03-01) -
New insights in the immunobiology of IL 1 family members
by: Frank Van De Veerdonk, et al.
Published: (2013-07-01) -
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
by: Frank L van de Veerdonk, et al.
Published: (2020-04-01) -
IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections.
by: Jeroen Slaats, et al.
Published: (2016-12-01) -
An open label trial of anakinra to prevent respiratory failure in COVID-19
by: Evdoxia Kyriazopoulou, et al.
Published: (2021-03-01)